• YM 58483 (BTP2): Interpreting SOCE Evidence

  2026-10-07

  YM 58483 (BTP2) is a store-operated calcium entry probe for connecting sustained Ca2+ influx with immune and fibrotic signaling. This article explains how to interpret its CRAC/TRP pathway effects, the ORAI2–JNK–NFAT1–TGF-β1 evidence, and the limits of pharmacologic inference.

• Tricine-SDS-PAGE Gel Preparation Kit Overview

  2026-10-06

  Product identity and stated conceptual scope for APExBIO’s K4136 Tricine-SDS-PAGE gel preparation kit, with no matched peer-reviewed paper evidence available.

• Dual SMAD and Wnt Inhibition for iPSC-RGCs

  2026-10-06

  Chavali et al. reported a chemically defined strategy that combines dual SMAD and canonical Wnt pathway inhibition to generate retinal ganglion cells (RGCs) from induced pluripotent stem cells (iPSCs) with improved yield and reproducibility. The study’s reported purity and functional characterization support the approach as a research platform for glaucoma biology, although the evidence remains in vitro and does not establish therapeutic efficacy.

• Drug Response Metrics in Cancer In Vitro

  2026-10-05

  Hannah Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent dimensions of an in vitro drug response. The work supports more careful interpretation of anticancer assays by emphasizing response magnitude, composition, and timing rather than treating a single viability value as a complete measure of drug activity.

• STING Agonist-1 and the B-Cell Immune Circuit

  2026-10-05

  New ESCC research positions STING within a broader CD40–TRAF2–IRF4 network that connects innate sensing with B-cell activation and tertiary lymphoid structure biology. This thought-leadership article examines what that finding establishes, where its evidence remains limited, and how STING agonist-1 can serve as a chemically defined research reagent for hypothesis-driven immunology, inflammation, and cancer studies—without confusing pathway interrogation with clinical validation.

• CHIR 99021 Trihydrochloride in Organoid Research

  2026-10-04

  A source-grounded overview of CHIR 99021 trihydrochloride as a GSK-3 inhibitor, emphasizing intestinal organoid research, stem-cell state regulation, evidence strength, conceptual applications, and important limitations.

• KCNE4-Dependent Modulation of Kv1.3 Pharmacology

  2026-10-03

  The 2024 Biochemical Pharmacology study shows that the auxiliary subunit KCNE4 changes how the Kv1.3 channel is inhibited without apparently changing blocker affinity. Its most important implication is that channel architecture and subunit composition can shape inhibition kinetics, complicating the interpretation of Psora 4 and other Kv1.3 blocker studies in immune cells.

• Regorafenib: From Kinase Map to Causal Biology

  2026-10-02

  Regorafenib (BAY 73-4506) is more than a broad-spectrum kinase inhibitor: it is a useful probe for connecting angiogenesis, invasion, apoptosis, and RRM2–ERK/E2F3 signaling. This article presents a causality-focused framework for cancer biology research that complements, rather than repeats, protocol-centered assay guides.

• EPZ-6438: A Framework for EZH2 Dependency

  2026-10-01

  EPZ-6438 is an EZH2 inhibitor for dissecting PRC2-driven transcriptional repression across cancer models. This article presents an assay-centered framework for connecting H3K27me3 loss with cell-state changes, HPV biology, and translational limitations.

• Cediranib (AZD2171) in Angiogenesis Assays

  2026-10-01

  Cediranib (AZD2171) supports mechanism-first studies of VEGFR-driven angiogenesis, from target-proximal phosphorylation to endothelial phenotypes and tumor-cell response. This workflow pairs pathway readouts with separate growth-arrest and cell-death measurements, reducing the risk of mistaking reduced proliferation for cytotoxicity.

• Liproxstatin-1 for Ferroptosis Research

  2026-09-30

  Liproxstatin-1 provides a practical way to separate ferroptotic lipid damage from apoptosis, oxidative stress, and emerging metal-dependent death pathways. This workflow-focused guide shows how to use it in viability assays, BODIPY-based lipid peroxidation measurements, GPX4-deficient cell protection studies, and renal injury models.

• HyperScribe T7 High Yield Cy5 RNA Labeling Kit Guide

  2026-09-30

  Build tunable Cy5-labeled RNA probes for in situ hybridization and Northern blot workflows while balancing fluorescent nucleotide incorporation against transcription yield. The workflow also shows how these probes can support spatial studies inspired by recent cleavage-resistant TREM2 macrophage research without confusing analytical labeling with therapeutic mRNA delivery.

• VNERi and Diastolic Pressure in Septic Shock

  2026-09-29

  Goury et al. proposed VNERi, calculated as diastolic arterial pressure divided by norepinephrine dose and heart rate, as a bedside-derived marker of vascular responsiveness. In a post-hoc analysis of early septic shock, VNERi showed stronger associations with mortality and organ-support-free outcomes than DAP, DAP/HR, or MAP divided by norepinephrine dose, while remaining an exploratory rather than treatment-directing index.

• 7ACC2 for MCT1 and Tumor Immunometabolism

  2026-09-29

  7ACC2 is a potent monocarboxylate transporter 1 inhibitor for dissecting lactate uptake, pyruvate flux, and metabolic stress in cancer models. This workflow-focused guide connects transporter assays with tumor-associated macrophage readouts while clearly separating established product evidence from exploratory immunometabolic applications.

• TaqI Restriction Endonuclease: Practical Guide

  2026-09-28

  TaqI Restriction Endonuclease (SKU K3053) provides rapid, sequence-specific cleavage of plasmid DNA, PCR products, and genomic DNA at the 5′…T↓CGA…3′ site. It is intended for research workflows such as DNA mapping, cloning, and fragment analysis, not for diagnostic or medical use.

8716 records 2/582 page Previous Next 12345 下5页 Last page